D-Rd in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes D-Rd in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes April 2025 Clinical trials Read more
2022 October Clinical trials Triple combination of obinutuzumab, acalabrutinib and venetoclax not (yet) recommended in pati... Read more
2022 October Clinical trials Lenalidomide plus rituximab is an efficient chemo-free alternative for patients with advanced ... Read more
2022 October Clinical trials Sutimlimab reduces haemolysis, anaemia, and fatigue in patients with CAD without transfusion r... Read more
2022 October Clinical trials MRD status post-ASCT as a powerful predictor of PFS and OS in patients with multiple myeloma Read more
2022 October Covid-19 Humoral responses against SARS-CoV-2 and variants of concern after vaccination in patients wit... Read more
Top
